The article ‘New type 2 diabetes drugs and their cardiovascular effects’ by Dr Emily Meyer and Associate Professor Stephen Stranks published in the April 2016 issue of Endocrinology Today (pages 24 to 27) contained an error. On page 24, the last Key Point should read:
- One study has shown that the use of the SGLT-2 inhibitor empagliflozin in patients with type 2 diabetes and established cardiovascular disease improves cardiovascular and all-cause mortality and heart failure outcomes.
As indicated within the article, studies to date have not shown that the use of empagliflozin improves stroke or myocardial infarction outcomes. We apologise to our readers for any confusion this error may have caused.
A corrected version of the article is available as a pdf on the Endocrinology Today website (www.endocrinologytoday.com.au).